Treating glaucoma and dry AMD with eye drops could create a multi-billion dollar market

New in vitro studies demonstrate Galimedix Therapeutics The company's developed small molecule MRZ-99030 can inhibit the misfolded A β regeneration, thereby reducing neurotoxicity. Foreign ophthalmology NGO Public data shows that, 2020 annually, there are nearly globally 8000 tens of thousands of glaucoma patients, 1.7 hundreds of millions of dry AMD patients, with a market size reaching tens of billions. Currently, the treatment for glaucoma only includes drugs and methods to lower IOP ； while dry AMD has yet to have an approved effective treatment.  

Galimedix company's research product delivers MRZ-99030 small molecule compounds directly to the retina via eye drops, potentially protecting the optic nerve to treat glaucoma and dry AMD and other degenerative diseases. Recently, at the Global Neuroscience Conference held in San Diego, USA Galimedix announced the latest research findings: the compound under its research MRZ-99030 (also known as GAL-101 ) can sustainably prevent the in vitro aggregation of misfolded amyloid-beta molecules into toxic forms and inhibit their toxicity to neural tissue.  

Galimedix 's co-founder, Doctor of Neuropharmacology Christopher Parsons said: Although the toxicity of amyloid-beta oligomers has been proven to play an important role in the progression of ophthalmic diseases including glaucoma and dry age-related macular degeneration. However, the research results announced at the Neuroscience Conference show that: MRZ-99030 Even after dilution a thousand times lower than the predicted therapeutic level, it can prevent the formation of these toxic oligomers, and even reverse their toxic effects by rapidly capturing misfolded proteins and transforming them into harmless "spots," continuing to work even after the drug is reduced below the minimum level. In clinical applications, this may prevent or reverse the progression of these diseases, which is groundbreaking.  

In this study, MRZ-99030 was proven to rapidly clear toxic molecules into harmless "spots," preventing further toxic effects on cells and improving neurofunctional deficits caused by toxic levels of misfolded amyloid-beta. It has also been proven safe in animal and in vitro models, as well as in clinical 1 phase trials in 70 patients.

Collecting "spots" and resuspending them in solution, maintaining the original concentration of misfolded amyloid-beta, diluting MRZ-99030 times 10 it was found that it could still block toxicity to cells and reverse the defects. After diluting four times to 1000 times, the misfolded amyloid-beta still maintained its original toxicity level. Currently, GAL-101 is preparing for glaucoma and dry AMD phase 2 studies.